Sequential hormonochemotherapy in advanced breast cancer

Por Hart, Lowell L
Publicado em 1988

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, place...

Por Herbst, Roy S, Ansari, Rafat, Bustin, Frederique, Flynn, Patrick, Hart, Lowell, Otterson, Gregory A, Vlahovic, Gordana, Soh, Chang-Heok, O’Connor, Paula, Hainsworth, John
Publicado em 2011

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma

Por Berdeja, Jesus G., Hart, Lowell L., Mace, Joseph R., Arrowsmith, Edward R., Essell, James H., Owera, Rami S., Hainsworth, John D., Flinn, Ian W.
Publicado no Haematologica (2015)

Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherap...

Por Yardley, Denise A., Hart, Lowell, Bosserman, Linda, Salleh, Mansoor N., Waterhouse, David M., Hagan, Maura K., Richards, Paul, DeSilvio, Michelle L., Mahoney, Janine M., Nagarwala, Yasir
Publicado em 2012

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type...

Por Eng, Cathy, Bessudo, Alberto, Hart, Lowell L., Severtsev, Aleksey, Gladkov, Oleg, Müller, Lothar, Kopp, Mikhail V., Vladimirov, Vladimir, Langdon, Robert, Kotiv, Bogdan, Barni, Sandro, Hsu, Ching, Bolotin, Ellen, von Roemeling, Reinhard, Schwartz, Brian, Bendell, Johanna C.
Publicado no Int J Cancer (2016)

A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer

Por Bendell, Johanna C., Hochster, Howard, Hart, Lowell L., Firdaus, Irfan, Mace, Joseph R., McFarlane, Joshua J., Kozloff, Mark, Catenacci, Daniel, Hsu, Jessie J., Hack, Stephen P., Shames, David S., Phan, See‐Chun, Koeppen, Hartmut, Cohn, Allen L.
Publicado no Oncologist (2017)

Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive p...

Por Forero-Torres, Andres, Infante, Jeffrey R, Waterhouse, David, Wong, Lucas, Vickers, Selwyn, Arrowsmith, Edward, He, Aiwu Ruth, Hart, Lowell, Trent, David, Wade, James, Jin, Xiaoping, Wang, Qiang, Austin, TaShara, Rosen, Michael, Beckman, Robert, von Roemeling, Reinhard, Greenberg, Jonathan, Saleh, Mansoor
Publicado em 2013

A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma

Por Ross, Helen J., Hart, Lowell L., Swanson, Paul M., Rarick, Mark U., Figlin, Robert A., Jacobs, Andrew D., McCune, David E., Rosenberg, Arthur H., Baron, Ari D., Grove, Laurie E., Thorn, Michael D., Miller, Dennis M., Drachman, Jonathan G., Rudin, Charles M.
Publicado em 2006

Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2

Por Beck, J. Thaddeus, Hortobagyi, Gabriel N., Campone, Mario, Lebrun, Fabienne, Deleu, Ines, Rugo, Hope S., Pistilli, Barbara, Masuda, Norikazu, Hart, Lowell, Melichar, Bohuslav, Dakhil, Shaker, Geberth, Matthias, Nunzi, Martina, Heng, Daniel Y. C., Brechenmacher, Thomas, El-Hashimy, Mona, Douma, Shyanne, Ringeisen, Francois, Piccart, Martine
Publicado em 2013